The efficacy and safety of glycosaminoglycan-peptide complex in patients with knee osteoarthritis and comorbidity: a multicenter prospective study
Эффективность и безопасность гликозаминогликан-пептидного комплекса у пациентов с остеоартритом коленного сустава и коморбидностью: многоцентровое проспективное исследование
2021-02-18
SCID: 54.1/j9b265jb
Discuss with AI
WOMAC indexglycosaminoglycan-peptide complexknee osteoarthritismulticenter prospective studysynovitis
Figures from the paper
Abstract (AI)
Objective: to evaluate the efficacy and safety of glycosaminoglycan-peptide complex (GPC, Rumalon) used in patients with knee osteoarthritis (OA) and comorbidities (hypertension and/or type 2 diabetes mellitus (T2DM). Patients and methods: A 10-month multicenter (13 centers from 10 subjects of the Russian Federation) prospective study included 179 patients with Stages II–III primary tibiofemoral knee OA and comorbidity, a walking pain intensity of ≥40 mm on a visual analogue scale (VAS), and a need for nonsteroidal anti-inflammatory drugs (for at least 30 days in the previous 3 months). The efficiency of treatment was evaluated from the changes in VAS scores for knee pain intensity during walking, the overall WOMAC score and scores of its individual indicators, laboratory parameters, and ultrasound data. All the patients received 2 cycles of GPC treatment with 25 injections, by following the manufacturer's instructions. Results and discussion. Even at 2 months after starting the treatment, there was a statistically significant reduction in pain during walking from 60 (50–69) to 40 (27–53.5) mm on the VAS (p< 0.05), which persisted during the follow-up period. A similar pattern was found when assessing the WOMAC index and its components. The drug demonstrated an anti-inflammatory effect: a decrease in the number of patients with synovitis from 55.7 to 39.2% (p=0.02), the level of high-sensitivity C-reactive protein (hsCRP) from 3.2 (1.3–6.2) to 2.6 (1.2–5.7) mg/l (p< 0.05). GPC was ascertained to have a safety profile. Conclusion. The data of this study confirm the good therapeutic effect and safety of GPC Rumalon in knee OA patients with hypertension and/or T2DM. The drug is shown to have a rapid analgesic and anti-inflammatory effect, as well as a positive influence on all clinical manifestations of OA.
Key Findings
1
A 10-month, 13-center prospective study evaluated two treatment cycles of glycosaminoglycan-peptide complex in 179 patients with stage II–III knee osteoarthritis and hypertension and/or type 2 diabetes.
2
Glycosaminoglycan-peptide complex improved the overall WOMAC index and its individual components, indicating benefits across multiple clinical manifestations of knee osteoarthritis.
3
The treatment demonstrated a favorable safety profile in patients with knee osteoarthritis and hypertension and/or type 2 diabetes.
4
Treatment showed anti-inflammatory effects, reducing synovitis prevalence from 55.7% to 39.2% and median high-sensitivity C-reactive protein from 3.2 to 2.6 mg/L.
5
Walking pain decreased significantly by two months, from a median VAS score of 60 to 40 mm, with improvement maintained throughout follow-up.
Research Object
Patients with stage II–III primary tibiofemoral knee osteoarthritis and comorbid hypertension and/or type 2 diabetes mellitus treated with glycosaminoglycan-peptide complex (GPC, Rumalon)
Research Subject
The efficacy and safety of GPC, including its analgesic, anti-inflammatory, clinical, functional, laboratory, and ultrasound effects
Publication Details
Publication Date
2021-02-18
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest